Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
Department of Endoscopy, Kobe University Hospital, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Surg Endosc. 2018 Apr;32(4):2123-2130. doi: 10.1007/s00464-017-5910-5. Epub 2017 Nov 2.
Endoscopic submucosal dissection (ESD) is a reliable method that can replace surgery under certain conditions. However, limited information is available on the clinical course of T1b colorectal cancer (CRC) after ESD. The aim of the study was to clarify the feasibility of ESD for T1b CRC.
Three hundred and two patients with 312 T1 CRC were identified in this retrospective cohort study. All patients were treated with ESD, other endoscopic treatments, or surgery. In this study, we (I) investigated the en bloc resection rate of ESD and (II) compared the overall survival (OS) rate for patients who underwent ESD with additional surgery (Group A) and surgery without upfront endoscopic resection (Group B) for T1b CRC.
No significant differences were observed in the en bloc resection rates between T1b and T1a CRC (100 vs. 98.7%), but the en bloc R0 resection rate was significantly lower in T1b CRC than in T1a CRC (64.7 vs. 97.4%). Regarding complications, perforations occurred in 2.9% of patients with T1b CRC, which was not significantly different from the rate of 5.3% in patients with T1a CRC. No significant differences were observed in the OS or recurrence-free survival (RFS) curves between Groups A and B (OS rates at 5 years: 92.3 vs. 88.9%, RFS rates at 5 years: 81.4 vs. 85.3%). Similarly, the 5-year disease-specific survival (DSS) rate of Group A was identical to that of Group B (both 100%).
ESD for T1b CRC before surgery is a possible strategy because of the low rate of complications and favorable long-term outcomes.
内镜黏膜下剥离术(ESD)是一种在某些情况下可以替代手术的可靠方法。然而,关于 ESD 后 T1b 结直肠癌(CRC)的临床过程,信息有限。本研究旨在阐明 ESD 治疗 T1b CRC 的可行性。
在这项回顾性队列研究中,共确定了 312 例 T1 CRC 患者中有 302 例接受了 ESD 治疗,其他内镜治疗或手术。在本研究中,我们(I)调查了 ESD 的整块切除率,(II)比较了 T1b CRC 患者中接受 ESD 加额外手术(A 组)与未行内镜切除的手术(B 组)的总生存率(OS)。
T1b 和 T1a CRC 的整块切除率无显著差异(100%比 98.7%),但 T1b CRC 的整块 R0 切除率明显低于 T1a CRC(64.7%比 97.4%)。关于并发症,T1b CRC 患者的穿孔发生率为 2.9%,与 T1a CRC 患者的穿孔发生率(5.3%)无显著差异。A 组和 B 组的 OS 或无复发生存(RFS)曲线无显著差异(5 年 OS 率:92.3%比 88.9%,5 年 RFS 率:81.4%比 85.3%)。同样,A 组的 5 年疾病特异性生存率(DSS)与 B 组相同(均为 100%)。
术前对 T1b CRC 进行 ESD 是一种可能的策略,因为并发症发生率低,且长期预后良好。